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Satomi Shiota1*†, Masako Ichikawa1†, Kazuhiro Suzuki2, Yoshinosuke Fukuchi1 and Kazuhisa Takahashi1Abstract
Background: We see patients who present with spirometry airflow limitation despite their forced expiratory volume in
one second (FEV1) as well as forced vital capacity (FVC) to be supernormal (FEV1/FVC < 70%, both the %FEV1 and the %
FVC ≧100%) in asymptomatic healthy non-smokers. Based on previous studies, we hypothesized these spirometry
conditions (results measured with spirometry) could be suitably used as a practical surrogate marker of pulmonary
dysanapsis: the condition of disproportionate but physiologically normal growth between airways and lung parenchyma.
Methods: We compared the conventional surrogate marker of dysanapsis, maximum mid-expiratory flow to FVC
(MMF/FVC), in SUBJECTS (FEV1/FVC < 70%, both the %FEV1 and the %FVC ≧100% in healthy non-smokers) (n = 25),
in EMPHYSEMA (CT confirmed pulmonary emphysema, same spirometry results with SUBJECTS) (n = 55), and in
CONTROLS (age- and height- matched, normal spirometry results) (n = 25). Next we added imaging analysis to
evaluate the relationship between the cross sectional airway luminal area (X-Ai) and the lung volume results
among the three groups.
Results: The MMF/FVC was significantly lower in SUBJECTS and in EMPHYSEMA compared to CONTROLS. However,
percent predicted peak expiratory flow (%PEFR) was significantly lower only in SUBJECTS and not in EMPHYSEMA
compared to CONTROLS. The ratio of the X-Ai of the trachea and right apical bronchus to lung volume was significantly
lower in SUBJECTS compared to CONTROLS.
Conclusion: The simple spirometry conditions in SUBJECTS are highly suggestive of practical surrogate marker of
pulmonary dysanapsis. Awareness of this concept would help to attenuate the risk of overdiagnosis of obstructive
pulmonary disease.
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A globally accepted definition of airflow limitation by
spirometry is when the forced expiratory volume in one
second divided by the forced vital capacity (FEV1/FVC)
ratio is less than 70%. In daily clinical situations, including
screening, we see patients who, from spirometry, present
with airflow limitation despite being in the supernormal.
percent predicted of FEV1 as well as FVC in healthy
non-smokers who have neither airway symptoms nor
any previous diagnosis of pulmonary disease. Thus, it is* Correspondence: sshiota@jutendo.ac.jp
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unless otherwise stated.difficult to correctly clarify their pathophysiological states
and may sometimes lead to overdiagnosis of obstructive
pulmonary disease. People with large lungs do not ne-
cessarily have larger airways than people with small
lungs. The concept of pulmonary dysanapsis was origin-
ally described as disproportionate but physiologically
normal growth between airways and lung parenchyma
[1]. Variability between individual’s lung volume and
airway size were accessed indirectly or directly [2,3].
Later, the ratio of maximal mid-expiratory flow to FVC
(MMF/FVC) has been accepted as a surrogate marker
of dysanapsis [4], based on the concept of this ratio’sThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Mead [2]. MMF/FVC can be obtained by conventional
spirometry, however this ratio has not been established
as a cut-off value to define dysanapsis. Furthermore,
this ratio is usually not present and not calculated on
conventional spirometry reports, making it difficult to
diagnose dysanapsis from these reports alone. We
focused on subjects that were healthy non-smokers, but
who presented with airflow limitation on spirometry
whilst having ‘supernormal’ percent predicted FEV1 as
well as FVC (FEV1/FVC < 70%, % FEV1 and FVC≧100%).
We hypothesized that this simple spirometry parameter
indicated and could be used as another practical surrogate
marker of pulmonary dysanapsis. We combined the evalu-
ation of spirometry results with the evaluation from im-
aging analysis on the above-mentioned subjects. We also
compared them to subjects with emphysema that had
similar spirometry findings and also to age- and height-
matched controls that had normal spirometry findings.
Methods & study subjects
We retrospectively reviewed male subjects, from April
2008 to April 2013, whose data were available for both
spirometry and for chest computed tomography (CT) in
our institute. We identified 25 asymptomatic healthy
non-smokers with normal CT image (SUBJECTS) and
55 CT-diagnosed pulmonary emphysema (EMPHY-
SEMA), both groups demonstrated airflow limitation
but FEV1 and FVC were still within the supernormal
percent predicted (i.e. FEV1/FVC < 70%, %FEV1 and %
FVC≧100%). The diagnosis of pulmonary emphysema
was based on the spirometric criteria of the Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD)
guideline [5] and by CT findings confirmed subjectively
by a respirologist and a radiologist. We also enrolled 25
asymptomatic healthy never-smokers who matched the
age and height (CONTROLS) of those who underwent
the annual health check. We only enrolled men con-
sidering gender differences of airways for a given lung
volume, even when corrected for age and height [2]. We
excluded patients who (i) did not complete both spirom-
etry and CT tests, (ii) had incomplete medical records,
(iii) had pulmonary disease including those with pul-
monary nodules of more than 3 cm in diameter, and (iii)
had image artifacts that could have potentially interfered
with image analysis. This retrospective and observational
study was approved by the ethics committee of our
institution. Spirometry was conducted according to the
American Thoracic Society (ATS) recommendations [6]
and to a standard technique using computerized pneumo-
tachograph based equipment (Minato Medical Science,
Osaka, JAPAN). The reference values obtained from the
Japanese population were utilized to calculate the %
predicted values [7]. Spirometry was not specificallycompleted after a bronchodilator. Sequential CT scans
were obtained using the 64-detectorrow CT scanner
(Aquilion-64; Toshiba Medical, Tokyo, Japan) with a 2-
to 10- mm slice thickness, scanning parameters of 120
kVp, auto exposure control (target SD 10), and a field of
view of 32 cm. All of SUBJECTS, EMPHYSEMA and
CONTROLS had undergone CT imaging to be evaluated
the lung parenchyma. Among them, we applied CT im-
aging analysis on 10 SUBJECTS, 21 EMPHYSEMA and 16
CONTROLS whose CT conditions were available to apply
imaging analysis software (Airway Inspector, Brigham and
Women’s Hospital, Boston, MA) [8]. The CT images in
this cohort study were reviewed by a respiratory specialist
and by a radiologist. We measured the cross sectional
airway luminal area (X-Ai) of the inner lumen and each
wall area (WA) percent [100 × ((total area-lumen area)/
total area)] at the 3 levels: (i) trachea above aortic arch
(Tr), (ii) right apical segmental bronchus (rB1) and, (iii)
right mediobasal segmental bronchus (rB7). These
levels were chosen because they were located in a plane
relatively perpendicular to the transverse plane of image
acquisition. Due to the wide range of slice thickness in
our clinically acquired CT data, we visually assessed the
severity of emphysema on CT according to the modified
Goddard scoring system [9], instead of assessing
Hounsfield Unit threshold using imaging analysis soft-
ware. Six images were analyzed in three slices in the lungs
and an average score of all images was considered as a
representative value of the severity of emphysema in each
person. Each image was classified as normal (score 0), (5%
affected (score 0.5), (25% affected (score 1), (50% affected
(score 2), (75% affected (score 3) and .75% affected (score
4), giving a minimum score of 0 and maximum of 4.
Statistical analysis of variance and kruskal-wallis test
were performed using SPSS Vers 20 (IBM, Chicago, IL).
Data were expressed as mean ± standard deviation. For all
statistical analysis, p value of less than .05 was considered
to show a statistically significant difference.Ethics
This project is retrospective medical data base research
and required to be notified to the research ethics commit-
tee. Ethics approval for the study was received from the
Juntendo University School of Medicine Research Ethics
Committee (No. 14–028).Results
The age-matched representative spirometry results of
SUBJECTS and EMPHYSEMA are shown in Figure 1A
and B, respectively. Between SUBJECTS and EMPHY-
SEMA, their FEV1/FVC results were closely matched.
Notably, on the other hand, %PEFR was clearly different
between the two groups.
Figure 1 Representative cases. A. Representative spirometry results of SUBJECTS. (75y.o., 159.1 cm, BSA 1.60 mm2, non-smoker). B. Representative
spirometry results of EMPHYSEMA. (74y.o., 160.7 cm, BSA 1.70 mm2, 78 packs per year tobacco history).
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tion, including age, height, body mass index (BMI) and
spirometry results are provided in Table 1. Unsurpris-
ingly, SUBJECTS and EMPHYSEMA showed higher
lung volume and lower FEV1/FVC compared to CON-
TROLS, as these was the initial enrollment criteria in
this study. MMF/FVC, which was the classical surro-
gate marker of dysanapsis, was significantly lower in
SUBJECTS as well as EMPHYSEMA compared to
CONTROLS. Notably, on the other hand, %PEFR
which relatively represents central airway, was signifi-
cantly lower only in SUBJECTS and not in EMPHY-
SEMA compared to CONTROLS as we presented in
Figure 1. In addition, MMF which relatively representssmall airway was higher in SUBJECTS compared to
EMPHYSEMA. The mean modified Goddard score was
1.53 (1.00-2.67) in EMPHYSEMA (data not shown).
Descriptive characteristics of the available study popula-
tion who underwent CT imaging analysis were provided
in Table 2. The average time interval between spirometry
and CT was 7.7 months. Similar results to those in Table 1
were found. Descriptive characteristics, focusing on the
ratio of X-Ai to lung volume by CT imaging analysis, were
provided in Table 3 and graphed in Figure 2. The ratio of
the inner X-Ai to lung size at the level of Tr and rB1 were
found to be significantly lower in both SUBJECTS and
EMPHYSEMA, compared to CONTROLS. Even at the
level of rB7, the ratio of the inner X-Ai to lung volume
Table 1 Patient’s characteristics and Spirometry results
SUBJECTS (n = 25) EMPHYSEMA (n = 55) CONTROLS (n = 25)
Age, years 72.8 ± 7.0† 68.2 ± 7.4 71.0 ± 7.7
Height, cm 166.0 ± 7.8 168.2 ± 5.9 165.8 ± 5.9
BMI, kg/mm2 22.7 ± 2.7** 22.2 ± 2.6‡‡ 26.0 ± 3.8
BSA, mm2 1.7 ± 0.2 1.7 ± 0.1 1.8 ± 0.2
VC, %pred 120.4 ± 9.8** 125.2 ± 9.8‡‡ 100.3 ± 16.0
FVC, %pred 114.7 ± 8.2** 119.4 ± 8.1‡‡ 95.6 ± 15.4
FEV1, %pred 106.1 ± 7.1 105.4 ± 5.8 101.5 ± 13.8
FEV1/FVC, % 67.2 ± 2.6** 65.6 ± 3.2‡‡ 78.6 ± 4.3
PEFR, %pred 99.6 ± 13.8** 104.9 ± 10.1 111.6 ± 18.1
MMF, %pred 48.6 ± 7.7**†† 43.9 ± 6.0‡‡ 76.2 ± 19.8
V50/V25 4.6 ± 1.46 4.38 ± 1.11 4.21 ± 1.22
ATI 4.61 ± 3.7 4.52 ± 2.96 5.22 ± 2.94
MMF/FVC 0.37 ± 0.05**†† 0.33 ± 0.05‡‡ 0.88 ± 0.17
Values are mean ± SD. BMI, body mass index; BSA, body surface area; VC, vital
capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; PEFR, peak expiratory flow; MMF, maximal mid-expiratory flow; V50 and V25,
Maximum expiratory flow rates at 50% and 25% of the FVC; ATI, air trapping index.
**Significantly different from CONTROLS (p < 0.01). ††Significantly different from EMPHYSEMA (p < 0.01). †Significantly different from EMPHYSEMA (p < 0.05).
‡‡Significantly different from CONTROLS (p < 0.01).
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compared to CONTROLS (Figure 2). WA % showed no
significant difference among the three groups.
Discussion
Main findings
In the present clinical study, some novel observations
could be made. Firstly, compared to CONTROLS, SUB-
JECTS showed significantly lower MMF/FVC ratio which
has been previously reported as a surrogate marker
of pulmonary dysanapsis [4]. Secondly, compared toTable 2 Descriptive characteristics of the available study pop
Group SUBJECTS (n = 10) EMPHYS
Age, years 72.6 ± 7.2 67.1
Height, cm 168.4 ± 10.5 168.2
BMI, kg/mm2 22.2 ± 1.9* 22.0
BSA, mm2 1.7 ± 0.2 1.7
VC, %pred 118.9 ± 10.0** 122.9
FVC, %pred 114.7 ± 9.9* 119.2
FEV1, %pred 106.8 ± 8.6 105.0
FEV1/FVC, % 67.7 ± 2.1** 65.8
PEFR, %pred 94.4 ± 14.8** 104.8
MMF, %pred 51.7 ± 8.1** 44.2
V50/V25 4.5 ± 1.9 4.6
ATI 3.5 ± 3.8 3.0
MMF/FVC 0.39 ± 0.05** †† 0.34
Values are mean ± SD. For definition of abbreviations see Table 1.
**Significantly different from CONTROLS (p < 0.01).
* Significantly different from CONTROLS (p < 0.05).
††Significantly different from EMPHYSEMA (p < 0.01). ‡‡Significantly different from CCONTROLS, SUBJECTS also showed a significant
lower ratio of airway size to lung volume at the level of
Tr and rB1, which is the principle concept of ‘dysanap-
sis condition’. Thirdly, EMPHYSEMA, with the same
spirometry conditions, also showed a significant lower
MMF/FVC ratio and a lower ratio of airway size to lung
volume at the level of Tr, rB1 and rB7 compared to
CONTROLS, while percent predicted PEFR was signifi-
cantly lower only in SUBJECTS and not in EMPHYSEMA,
compared to CONTROLS. Fourthly, EMPHYSEMA in our
study included variable levels of low attenuation areasulation who underwent CT analysis
EMA (n = 21) CONTROLS (n = 16)
± 6.0 69.8 ± 8.7
± 5.8 167.1 ± 6.4
± 3.2‡‡ 26.0 ± 3.4
± 0.1 1.8 ± 0.2
± 8.8‡‡ 99.6 ± 14.1
± 8.0 †† 95.2 ± 13.0
± 6.3 101.7 ± 11.3
± 3.1‡‡ 79.6 ± 4.2
± 10.0 114.9 ± 18.4
± 5.5‡‡ 80.2 ± 19.9
± 1.3 4.0 ± 1.2
± 1.9 4.2 ± 2.4
± 0.04‡‡ 0.75 ± 0.17
ONTROLS (p < 0.01).
Table 3 Descriptive characteristics, focusing on the ratio of airway X-Ai to lung volume of the available study
population who underwent CT analysis
Group SUBJECTS (n = 10) EMPHYSEMA (n = 21) CONTROLS (n = 16)
Tr, WA, % 21.0 ± 3.6 22.1 ± 5.6 22.4 ± 3.1
rB1 WA, % 52.1 ± 5.1 49.1 ± 5.0 49.6 ± 4.4
rB7 WA, % 51.8 ± 3.7 51.4 ± 4.64 50.9 ± 3.8
TrX-Ai/VC 44.8 ± 11.5* 44.2 ± 15.3$$ 61.3 ± 20.3
Tr X-Ai /FVC 46.5 ± 12.4* 45.6 ± 15.9$$ 64.0 ± 21.2
rB1X-Ai /VC 5.45 ± 2.30* 6.05 ± 2.05$ 8.0 ± 2.3
rB1X-Ai /FVC 5.62 ± 2.28* 6.23 ± 2.09$ 8.3 ± 2.5
rB7 X-Ai /VC 5.34 ± 1.16 5.26 ± 1.51$ 6.80 ± 1.85
rB7X-Ai /FVC 5.52 ± 1.1 2 5.43 ± 1.58$ 7.09 ± 1.92
Values are mean ± SD. Trachea; Tr, Wall area; WA, Right B1; rB1, Right B7; rB7, inner cross sectional luminal area at trachea; TrX-Ai, inner cross sectional luminal area
at rB1; rB1 X-Ai, inner cross sectional luminal area at rB7; rB7 X-Ai.
* Significantly different from CONTROLS (p < 0.05).
$Significantly different from CONTROLS (p < 0.05).
$$Significantly different from CONTROLS (p < 0.01).
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pite all to be at the stage I level of chronic obstructive
pulmonary disease (COPD) under the GOLD guidelines
[5] (FEV1/FVC ratio in EMPHYSEMA in our study
ranged from 58.4% to 69.9%).
Strengths and limitations of this study
Since the slice thickness of our retrospectively acquired
data ranged from 2 to 10 mm, this thickness might likely
confound any measure of the intra-parenchymal airways
size since very few are truly straight in the Z direction
for such a distance. Those ranges of the slice thickness
among subjects partially might explain why ratio of air-
way size to lung volume at rB7 between SUBJECTS andFigure 2 The cross sectional airway luminal area (X-Ai) to lung volum
abbreviations see Table 1 and Table 3.CONTROLS did not show a significantly difference. Be-
cause of the same reason, we could not directly measure
lung volume. Nevertheless, the trachea was stable even
in measuring 2–10 mm slice thicknesses. Thus, dysanap-
tic lung development is evident in SUBJECTS.
An abnormally low FEV1/FVC ratio is universally ac-
cepted as indicative of obstructive lung disease. Before
recent revision, defining severity of stage I COPD has
been set based solely on an FEV1/FVC less than 70%
and FEV1 above 80% predicted irrespective of age [10].
However, later studies reported these criteria do not
always work correctly [11]. The 2005ATS/ERS task force
report defined obstructive abnormalities using the lower
limit of normal (LLN), less than the 5th percentilee at the level of Trachea, right B1 and right B7. For definition of
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Although predictive equations for LLN of FEV1/FVC
were variable [6] that is the estimation of the LLN from
the different predicted normal equations gave variable
results, SUBJECTS in our study were judged as within
normal when we applied some of those criteria. This
might suggest a physiological explanation behind the
clinical significance of using LLN as the definition of ob-
struction. Nevertheless, the GOLD criteria still have
been utilized widely in daily clinical practice including
evaluation of pulmonary function test. The strength of
our study lays in that the simple spirometry criteria
which we set helps to explain the principle concept of
dysanapsis as the normal variation of pulmonary me-
chanics. Due to its disproportionate growth between
airway size to lung parenchyma, dysanapsis may lead to
overdiagnosis of obstructive pulmonary disease in the
situation where the GOLD criteria is used. In other
words, we can attribute it as one of the possible causes
of spirometry defined airflow limitation within the nor-
mal variation for healthy people. Awareness of these
concept would help to interpret spirometry findings
more accurately and may help to attenuate the risk of
overdiagnosis in daily clinical practice, such as at health
check up and/or preoperative screening processes.
We would like to acknowledge several limitations of
our study. Our small sample size might have an effect
on the study result. In addition, we could not assess the
reversibility in airflow limitation, a recommended criter-
ion for defining COPD [6]. Nevertheless, it is unlikely
that SUBJECTS show the reversibility since none has
any respiratory symptoms since birth and all are con-
firmed with normal lung field by chest CT. Furthermore,
considering medical ethics of burdening invasion, it is
beyond our scope to use the bronchodilator as part of
the screening process. Furthermore, since we compared
airway size at inhalation and the degree of airflow limita-
tion at forced expiration, contribution of tracheal col-
lapsibility was not accounted for. Small difference
between the ratio of X-Ai to VC and the ratio of X-Ai to
FVC may partially explain those contributions.
Interpretation of findings in relation to previously
published work
It is important to note the pathophysiology of SUBJECTS.
Maximum airflow (Vmax) reflects the mechanical proper-
ties of lungs and airways [12,13]. It is determined by the
static lung recoil pressure (Pst (l)) at that volume and the
upstream resistance (Rus) between the alveoli and the
equal pressure points (choke point) where intrabronchial
pressure equals pleural pressure [14]. The Pst (l) depends
on the absolute lung volume [15]. The larger FVC (≧100%
of predicted FVC) influences the larger Pst (l) and the
smaller airway area guides the higher Rus at the beginningof expiration. These would induce the reduction of
maximum flow, and subsequently, a longer time to
complete exhalation would be needed to produce FVC.
Nevertheless, despite taking longer, they will still be able
to produce more than 100% of predicted FEV1 as well
as FVC since their driving pressure: Pst (l) is super nor-
mal. A relatively smaller X-Ai could lead to a reduction
of expiratory maximum flow and to a decreased ratio of
FEV1 to FVC, because the emptying rate of the lungs
amortised over one second will be decreased due to the
reduction of PEFR. Indeed, in healthy subjects PEFR
predominantly reflects the caliber of large airways [16]
and shows the significant positive correlation between
tracheal size and PEFR [1,14,17]. This could explain the
significant reduction of %PEFR in SUBJECTS but not in
EMPHYSEMA compared to CONTROLS in our study
results. Although we did not evaluate the expiratory
time in our study, a previous study showed a longer
expiratory time in the subjects who were suggested as
dysanapsis [18], which support our idea.
As for origin of pulmonaly dysanapsis, its congenital
basis as one of possibilities has been reported. Chen et al.
[19], using segregation analysis of Vmax50 (the maximal
expiratory flow rate at 50% of total volume) /FVC as a
surrogate marker of dysanapsis, suggested that dysanap-
tic growth of the airways to parenchyma is under major
gene control. Silverman et al. [20] showed significant
linkage of FEV1/FVC to chromosome 2q could reflect
one or more genes influencing the development of air-
flow obstruction or dysanapsis. Recently, Klimentidis
et al. [21] found that the heritability for FEV1/FVC was
considerably higher than the one for either FEV1 or
FVC and demonstrated that genetic factors account for
a sizable proportion of inter-individual differences in
pulmonary function.
Implications for future research, policy and practice
Dysanapsis could have a role in the pathogenesis of
COPD [1] and asthma [22,23]. Observational study later
showed that sons of COPD patients had a lower ratio of
airway size to lung volume [24,25]. Thus, larger lungs
are not necessarily advantageous unless the airway pro-
portionally grows. Dysanapsis could be one of the risk
for development of COPD, in addition to the generally
accepted airflow limitation risks for COPD related with
alternation of airway diameter secondary to airway re-
modeling [26,27]. Enrolled EMPHYSEMA in our study
had a significant smaller ratio of airway size to lung
volume compared to CONTROL when they showed
variable levels of LAA on their chest CT. Actually, the
severity of emphysematous lesion does not necessary
reflect the airflow limitation defined by spirometry [28].
Dysanapsis could partially explain airflow limitation in
our EMPHYSEMA patients, in addition to the elastic
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addition, annual decline of FEV1 is accelerated earlier
than that of FVC [29]. The age-related effects on the
lower FEV1/FVC is associated with an increase in tra-
cheal cross sectional area [30-32], a decrease in airway
radial distensibility [32,33] and elastic recoil [14,34-36].
However, age-related effects were less likely to have an
effect on our study results because the study groups
were adjusted for age.
Conclusions
Our current study results suggest that spirometry defined
airflow limitation by GOLD criteria with more than 100%
of predicted FEV1 and FVC may suggest pulmonary dysa-
napsis as the normal variation in asymptomatic healthy
subjects. Additional epidemiologic and physiologic studies
with a large sample size are warranted in order to corrob-
orate our results.
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